Compugen Share Price Today
(NASDAQ: CGEN)

Name: Compugen Share Price Today (NASDAQ: CGEN) - Compugen Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Compugen share price is $1.52 & ₹128.63 as on 2 May 2025, 2.30 'hrs' IST

$1.52

▲

-0.08

(-5%)

Market is closed - opens 7 PM, 02 May 2025

View live Compugen share price in Dollar and Rupees. Guide to invest in Compugen stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Compugen, along with analyst recommendations, forecasts, and comprehensive financials.

Compugen share price movements

Today's Low: $1.51
Today's High: $1.60
$1.52
0.66%
Downside
Day's Volatility :5.63%
Upside
5.0%
52 Weeks Low: $1.13
52 Weeks High: $2.66
$1.52
25.66%
Downside
52 Weeks Volatility :57.52%
Upside
42.86%

Compugen (CGEN) Returns

Period	Compugen Ltd	Sector (Health Care)	Index (Russel 2000)
3 Months	-32.4%	-4.4%	0.0%
6 Months	-7.89%	-5.0%	0.0%
1 Year	-27.08%	-0.1%	0.0%
3 Years	-31.52%	7.8%	-5.1%

Compugen (CGEN) Key Statistics

in dollars & INR

Previous Close	$1.6
Open	$1.6
Today's High	$1.6
Today's Low	$1.51
Market Capitalization	$134.7M
Today's Volume	$336.5K
52 Week High	$2.66
52 Week Low	$1.13
Revenue TTM	$27.9M
EBITDA	$-14.4M
Earnings Per Share (EPS)	$-0.16
Profit Margin	-51.07%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-23.63%

How to invest in Compugen Stock (CGEN) from India?

It is very easy for Indian residents to invest directly in Compugen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Compugen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Compugen or CGEN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Compugen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Compugen shares which would translate to 0.557 fractional shares of Compugen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Compugen, in just a few clicks!

Returns in Compugen (CGEN) for Indian investors in Rupees

The Compugen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Compugen investment value today

Current value as on today

₹71,787

Returns

₹28,213

(-28.21%)

Returns from Compugen Stock

₹29,630 (-29.63%)

Dollar Returns

₹1,417 (+1.42%)

Indian investors sentiment towards Compugen (CGEN)

-36%

Period: Apr 1, 2025 to May 1, 2025. Change in 30 Days versus previous period

Search interest for Compugen Stock from India on INDmoney has decreased by -36% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Compugen

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Compugen(by analysts ranked 0 to 5 stars)

Analyst Forecast on Compugen Stock (CGEN)

What analysts predicted

Upside of 163.16%

Target:

$4.00

Current:

$1.52

Insights on Compugen Stock (Ticker Symbol: CGEN)

Price Movement
In the last 7 days, CGEN stock has moved up by 6.4%
CGEN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 96.5%
CGEN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 97.3% return, outperforming this stock by 131.1%
Price to Sales
ForCGEN every $1 of sales, investors are willing to pay $4.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.5 for every $1 of sales.

Compugen Technicals Summary

Sell

Neutral

Buy

Compugen is currently in a neutral trading position according to technical analysis indicators.

Compugen (CGEN) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Compugen Ltd	7.88%	-7.89%	-27.08%	-31.52%	-89.46%
Biontech Se	11.56%	-6.61%	12.87%	-30.24%	127.41%
Regeneron Pharmaceuticals, Inc.	-4.3%	-29.03%	-36.14%	-9.35%	10.5%
Vertex Pharmaceuticals Incorporated	5.32%	8.08%	27.25%	89.22%	92.38%
Alnylam Pharmaceuticals, Inc.	-1.34%	-3.89%	75.14%	84.24%	92.68%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Compugen Ltd	60.33	NA	0.0	-0.23	-0.24	-0.08	NA	0.61
Biontech Se	160.8	NA	0.04	-5.11	-0.03	-0.04	NA	80.89
Regeneron Pharmaceuticals, Inc.	15.94	15.94	0.96	39.38	0.16	0.07	0.01	273.57
Vertex Pharmaceuticals Incorporated	32.84	NA	1.38	17.94	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.72	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Compugen Ltd	Buy	$134.7M	-89.46%	60.33	-51.07%
Biontech Se	Buy	$29.5B	127.41%	160.8	-24.18%
Regeneron Pharmaceuticals, Inc.	Buy	$66.5B	10.5%	15.94	31.07%
Vertex Pharmaceuticals Incorporated	Buy	$129.4B	92.38%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$33.3B	92.68%	NA	-12.37%

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Organization	Compugen
Employees	74
CEO	Dr. Anat Cohen-Dayag Ph.D.
Industry	Health Technology

Management People of Compugen

Name	Title
Dr. Anat Cohen-Dayag Ph.D.	CEO, President & Director
Dr. Eran Ophir Ph.D.	Chief Scientific Officer
Dr. Zurit Levine Ph.D.	Senior Vice President of Strategic Collaborations
Dr. Pierre Ferre Ph.D.	Senior VP of Preclinical Development & Corporate Operations
Ms. Michelle Mahler M.D.	Chief Medical Officer
Mr. David Silberman CPA	Chief Financial Officer
Ms. Yvonne Naughton	Head of Investor Relations & Corporate Communications
Mr. Eran Ben Dor	General Counsel & Corporate Secretary
Ms. Dorit Amitay	Vice President of Human Resources
Dr. Yaron Turpaz M.B.A., Ph.D.	Senior VP & Senior Advisor of Data and Informatics Solutions

Important FAQs about investing in CGEN Stock from India :

What is Compugen share price today?

Compugen share price today stands at $1.52, Open: $1.60 ; Previous Close: $1.60 ; High: $1.60 ; Low: $1.51 ; 52 Week High: $2.66 ; 52 Week Low: $1.13.

The stock opens at $1.60, after a previous close of $1.60. The stock reached a daily high of $1.60 and a low of $1.51, with a 52-week high of $2.66 and a 52-week low of $1.13.

Can Indians buy Compugen shares?

Yes, Indians can invest in the Compugen (CGEN) from India.

With INDmoney, you can buy Compugen at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Compugen at zero transaction cost.

How can I buy Compugen shares from India?

It is very easy to buy Compugen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Compugen (CGEN) be purchased?

Yes, you can buy fractional shares of Compugen with INDmoney app.

What are the documents required to start investing in Compugen stocks?

To start investing in Compugen, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.